en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2007
vol. 45
 
Share:
Send email
Share:
abstract:

Review paper
The role of abatacept in the treatment of rheumatoid arthritis

Piotr Wiland
,
Bożena Kowalewska
,
Eliza Roszkowska
,
Jacek Szechiński

Reumatologia 2007; 45, 4: 205–214
Online publish date: 2007/08/30
View full text Get citation
 
Although the development of disease-modifying antirheumatic drugs (DMARDs) and tumour necrosis factor antagonists has improved the clinical outcome of many patients with rheumatoid arthritis (RA), a substantial proportion of patients have an inadequate response. As T cells promote numerous disease pathways in RA, these cells are a logical target for anti-inflammatory therapy. Abatacept (CTLA-4Ig) is a soluble recombinant fusion protein which competes with CD28 for CD80 and CD86 binding and thereby can be used to selectively modulate T-cell activation. Several clinical trials have now confirmed the efficacy of this compound in the treatment of RA. This article discusses the mechanism of action and reviews the data from large clinical trials on the efficacy and safety of abatacept in RA.
keywords:

rheumatoid arthritis, lymphocyte T, abatacept, CD28 antigen
EVENTS/KONFERENCJE
BOOKS/KSIĄŻKI



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.